Eli Lilly (LLY) is in advanced talks to acquire Kelonia Therapeutics for more than $2 billion, according to the Wall Street Journal, citing people familiar with the matter. A deal could be announced as soon as Monday, though the talks may still fall apart. The price may also include additional milestone-based payments if Kelonia achieves certain targets, the report said.
Kelonia Therapeutics is a private biotechnology company based in Cambridge, Massachusetts.
LLY closed at $927.03, rising $23.04 or 2.55% as of April 17. In overnight trading at 8:46:55 PM EDT, the stock slipped to $921.50, down $5.53 or 0.60%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.